Exposures aimed at compensating for these metabolically compromised cellular states may improve the vascular consequences facing APOL1 variant carriers, and may be particularly important in those people with inflammatory, infectious, or autoimmune diseases. This evidence concerns the gene APOL1 and autoimmune disease.